Literature DB >> 19419141

Discovery of 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a novel positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor.

Ramin Faghih1, Sujatha M Gopalakrishnan, Jens Halvard Gronlien, John Malysz, Clark A Briggs, Caroline Wetterstrand, Hilde Ween, Michael P Curtis, Kathy A Sarris, Gregory A Gfesser, Rachid El-Kouhen, Holly M Robb, Richard J Radek, Kennan C Marsh, William H Bunnelle, Murali Gopalakrishnan.   

Abstract

The discovery of a series of pyrrole-sulfonamides as positive allosteric modulators (PAM) of alpha7 nAChRs is described. Optimization of this series led to the identification of 19 (A-867744), a novel type II PAM with good potency and selectivity. Compound 19 showed acceptable pharmacokinetic profile across species and brain levels sufficient to modulate alpha7 nAChRs. In a rodent model of sensory gating, 19 normalized gating deficits. These results suggest that 19 represents a novel class of molecules capable of allosteric modulation of the alpha7 nAChRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419141     DOI: 10.1021/jm9003818

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-06-29       Impact factor: 5.269

3.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

Review 4.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

5.  Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.

Authors:  D B Timmermann; K Sandager-Nielsen; T Dyhring; M Smith; A-M Jacobsen; E Ø Nielsen; M Grunnet; J K Christensen; D Peters; K Kohlhaas; G M Olsen; P K Ahring
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

6.  Positive allosteric modulation of alpha7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons.

Authors:  Min Hu; Murali Gopalakrishnan; Jinhe Li
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

7.  A positive allosteric modulator of α7 nAChRs augments neuroprotective effects of endogenous nicotinic agonists in cerebral ischaemia.

Authors:  Bopanna I Kalappa; Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats.

Authors:  Eric G Mohler; Stanley R Franklin; Lynne E Rueter
Journal:  Psychopharmacology (Berl)       Date:  2013-08-08       Impact factor: 4.530

Review 9.  Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.

Authors:  Anshul A Pandya; Jerrel L Yakel
Journal:  Biochem Pharmacol       Date:  2013-05-31       Impact factor: 5.858

Review 10.  Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.

Authors:  Ana Sofía Vallés; María Virginia Borroni; Francisco J Barrantes
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.